News

Point of Care Decision Support, anticoagulation software, PCDS AC, therapy

Point of Care Anticoagulation software (PCDS AC) optimizes delivery of anticoagulation (AC) drugs and reduces adverse events associated with anticoagulation therapy.

atrial fibrillation, women, seniors, guidelines, blood thinners, DCRI

Nearly all women and people over 65 in the United States with atrial fibrillation are advised to take blood thinners under new guidelines based on an analysis from the Duke Clinical Research...

Merck announced results from two post-hoc analyses of the TRA 2°P TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) trial of Zontivity (vorapaxar...

Xarelto, rivaroxaban, Starter Pack, FDA, deep vein thrombosis, pulmonary embolis

The U.S. Food and Drug Administration (FDA) has approved the Xarelto Starter Pack for deep vein thrombosis (DVT) and/or pulmonary embolism (PE) treatment. The starter pack was designed to help...

Nanometer-sized “drones” could become a new way to prevent heart attacks caused by atherosclerosis, according to a study in pre-clinical models by scientists at Brigham and Women’s Hospital (BWH)...

Patients who experienced a certain type of heart attack who received the anticoagulant fondaparinux had a lower risk of major bleeding events and death compared to patients who received low-...

nanoparticles, stroke, tPA, blood clot, magnetic, MRI, antiplatelet

By loading magnetic nanoparticles with drugs and dressing them in biochemical camouflage, Houston Methodist researchers say they can destroy blood clots 100 to 1,000 times faster than a commonly...

Symphony Health Solutions (SHS) and the American College of Cardiology announced the completion of a new research platform. The HIPAA-compliant platform combines anonymized patient-level data from...

Millions of people take angiotensin receptor blockers (ARBs) to help treat heart failure. But it turns out not all ARBs are created equally, according to one Nova Southeastern University (NSU)...

antiplatelet therapy, pharmaceuticals, cath lab, clinical trial, ticagrelor

AstraZeneca announced that the PEGASUS-TIMI 54 study, a large-scale outcomes trial involving more than 21,000...

rivaroxaban, Xarelto, safety performance, Janssen, NVAF

A new post-marketing study evaluating the safety of once-daily rivaroxaban (Xarelto) shows, in patients with non-valvular atrial fibrillation (NVAF), rates and patterns of major...

More than 10 percent of patients treated with aspirin therapy for primary cardiovascular disease prevention were likely inappropriately prescribed medication, according to a new study in the...

Savaysa, Daiichi Sankyo, edoxaban, FDA, approval, NVAF, thromboembolism

Daiichi Sankyo Co. Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Savaysa (edoxaban) tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of...

Discussions regarding late-breaking cardiovascular clinical trials among leading medical scientists are placing considerable emphasis on individualized patient care, particularly in the area of...

Wearable technologies, possible changes to stenting practices, state legislation on energy drinks, expanded use of minimally invasive heart repair procedures, and the development of a new class of...

The most accessed research studies in the Journal of the American College of Cardiology (JACC) in 2014 spanned many topics, including a blood test to rule out heart attack, an advisory...

Alere, INRatio, INRatio2, PT/INR Monitor system, correction

Alere Inc. has initiated a voluntary correction to inform United States users of the Alere INRatio and INRatio 2 PT/INR Monitor system of certain medical conditions that should not be tested with...

NHLBI, Losartan, Marfan syndrome, atenolol

A National Institutes of Health-funded study comparing treatment with widely used blood pressure medications, atenolol or losartan, in patients with Marfan syndrome who had an enlarged aortic root...

AHA, warfarin, antiplatelet therapy, atrial fibrillation, anti-clotting, EP lab

Long-term overtreatment with the anti-clotting drug warfarin combined with antiplatelet therapy to prevent stroke may raise the risk of dementia in people with atrial fibrillation.

DAPT study

Patients who took dual antiplatelet therapy medications beyond the standard 12 months after coronary stent placement were significantly less likely to develop blood clots within their stents or to...